최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Korean journal of microbiology = 미생물학회지, v.49 no.1, 2013년, pp.17 - 23
Candida biofilms are organized microbial communities growing on the surfaces of host tissues or indwelling medical devices, and the biofilms show enhanced resistance against the conventional antifungal agents. The roots of Coptidis chinensis have been widely used for medicinal purposes in East Asia....
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
C. albicans는 어떤 독성인자를 가지고 있습니까? | C. albicans는 숙주 조직에 침입하거나 숙주의 방어기작을 회피하게 하는 독성인자를 가지고 있는 다재다능한 병원성 미생물 로서 이들이 가지는 독성인자로는 숙주 상피세포로의 부착을 매개하는 다양한 표면구조의 표현, 단세포성 효모형과 필라멘트성 균사형으로의 상호 형태변화 능력, 바이오필름 형성능력, 아스 파르트산 단백질 분해효소나 phospholipase와 같은 가수분해효 소의 분비, 환경변화에 대한 반응성 등을 들 수 있다(Calderone and Fonzi, 2001; Haynes, 2001). | |
Candida albicans는 어떤 병원균입니까? | Candida albicans는 건강한 사람의 점막 상재균으로서, 심각한 질환에 걸렸거나 면역력이 약화된 환자에게 표재성 감염을 유발하며 점막상피를 통해 전신성 혈류감염을 유발하는 기회감 염균이다(Odds et al., 2001). | |
황련 수용성 추출물은 C. albicans의 무엇을 억제하였습니까? | C. chinensis 수용성 추출물은 살진균 활성을 나타냈고, C. albicans 바이오필름의 폴리스티렌 표면으로의 부착을 억제하였 으며 C. albicans를 G0/G1 기에 머무르게 하여 바이오필름이나 출아법에 의한 증식을 억제시켰다. 본 연구의 결과는 C. |
Baba, M., Osumi, M., Scott, S.V., Klionsky, D.J., and Ohsumi, Y. 1997. Two distinct pathways for targeting proteins from the cytoplasm to the vacuole/lysosome. J. Cell Biol. 139, 1687-1695.
Beggs, W.H. 1994. Physicochemical cell damage in relation to lethal amphotericin B action. Antimicrob. Agents Chemother. 38, 363-364.
Blankenship, J.R. and Mitchell, A.P. 2006. How to build a biofilm: a fungal perspective. Curr. Opin. Microbiol. 9, 588-594.
Calderone, R.A. and Fonzi, W.A. 2001. Virulence factors of Candida albicans. Trends Microbiol. 9, 327-335.
Chandra, J., Kuhn, D.M., Mukherjee, P.K., Hoyer, L.L., McCormick, T., and Ghannoum, M.A. 2001. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183, 5385-5394.
CLSI. 2008a. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-third edition; CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA, USA.
Cohen, B.E. 1998. Amphotericin B toxicity and lethality: a tale of two channels. Int. J. Pharmaceutics 162, 95-106.
Douglas, L.J. 2003. Candida biofilms and their role in infection. Trends Microbiol. 11, 30-36.
Edidin, M. 1970. A rapid, quantitative fluorescence assay for cell damage by cytotoxic antibodies. J. Immunol. 104, 1303-1306.
Eom, K.S., Hong, J.M., Youn, M.J., So, H.S., Park, R., Kim, J.M., and Kim, T.Y. 2008. Berberine induces G1 arrest and apoptosis in human glioblastoma T98G cells through mitochondrial/caspases pathway. Biol. Pharm. Bull. 31, 558-562.
Ghosh, A.K., Bhaktachoryya, F.K., and Ghosh, D.K. 1985. Amastigote inhibition and mode of action of berberine. Exp. Parasitol. 60, 404-413.
Gow, N.A.R. and Gooday, G.W. 1982. Vacuolation, branch production and linear growth of germ tubes form Candida albicans. J. Gen. Microbiol. 128, 2195-2198.
Guarrera, P.M. 2005. Traditional phytotherapy in central Italy. Fitotherapia 76, 1-25.
Haynes, K. 2001. Virulence in Candida species. Trends Microbiol. 9, 591-596.
Henry-Stanley, M.J., Garni, R.M., and Wells, C.L. 2004. Adaptation of FUN-1 and Calcofluor white stains to assess the ability of viable and nonviable yeast to adhere to and be internalized by cultured mammalian cells. J. Microbiol. Methods 59, 289-292.
Ikuta, A., Kobayashi, A., and Itokawa, H. 1984. Studies on the quantitative analysis of protoberberine alkaloids in Japanese, Chinese and other countries Coptis rhizomes by thin-layer chromatography-densitometry. Shoyakugaku zasshi 38, 279-282.
Jones, K.H. and Senft, J.A. 1985. An improved method to determine cell viability by simultaneous staining with fluorescein diacetate-propidium iodide. J. Histochem. Cytochem. 33, 77-79.
Kim, Y.M., Ha, Y.M., Jin, Y.C., Shi, L.Y., Lee, Y.S., Kim, H.J., Seo, H.G., Choi, J.S., Kim, Y.S., Kang, S.S., and et al. 2009. Palmatine from Coptidis rhizoma reduces ischemia-reperfusion-mediated acute myocardial injury in the rat. Food Chem. Toxicol. 47, 2097-2102.
Klepser, M.E., Ernst, E.J., Lewis, R.E., Ernst, M.E., and Pfaller, M.A. 1998. Influence of test conditions on antifungal time-kill curve results: proposal for standardized methods. Antimicrob. Agents Chemother. 42, 1207-1212.
Krishan, A. 1975. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J. Cell Biol. 66, 188-193.
Kuo, C.L., Chi, C.W., and Liu, T.Y. 2004. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 203, 127-137.
Lo, H.J., Kohler, J.R., DiDomenico, B., Loebenberg, D., Cacciapuoti, A., and Fink, G.R. 1997. Nonfilamentous C. albicans mutants are avirulent. Cell 90, 939-949.
Mackenzie, D.W.R. 1962. Serum tube identification of Candida albicans. J. Clin. Pathol. 15, 563-565.
Mantena, S.K., Sharma, S.D., and Katiyar, S.K. 2006. Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Mol. Cancer Ther. 5, 296-308.
Mathur, A., Singh, R., Yousuf, S., Bhardwaj, A., Verma, S.K., Babu, P., Gupta, V., Prasad, G.B.K.S., and Dua, V.K. 2011. Antifungal activity of some plant extracts against clinical pathogens. Adv. Appl. Sci. Res. 2, 260-264.
Millard, P.J., Roth, B.L., Thi, H-P., Yue, S.T., and Haugland, R.P. 1997. Development of the FUN-1 family of fluorescent probes for vacuole labeling and viability testing of yeast. Appl. Environ. Microbiol. 63, 2897-2905.
Odds, F.C., Gow, N.A., and Brown, A.J. 2001. Fungal virulence studies come of age. Genome Biol. 2, reviews 1009.1-1009.4.
Oliver, B.G., Silver, P.M., Marie, C., Hoot, S.J., Leyde, S.E., and White, T.C. 2008. Tetracycline alters drug susceptibility in Candida albicans and other pathogenic fungi. Microbiology 154, 960-970.
Perea, S. and Patterson, T.F. 2002. Antifungal resistance in pathogenic fungi. Clin. Infect. Dis. 35, 1073-1080.
Pfaller, M.A. and Diekema, D.J. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20, 133-163.
Ramage, G., Martinez, J.P., and Lopez-Ribot, J.L. 2006. Candida biofilms on implanted biomaterials: a clinically significant problem. FEMS Yeast Res. 6, 979-986.
Ramage, G., Vande-Walle, K., Wickes, B.L., and Lopez-Ribot, J.L. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45, 2475 -2479.
Rotman, B. and Papermaster, B.W. 1966. Membrane properties of living mammalian cells as studied by enzymatic hydrolysis of fluorogenic esters. Proc. Natl. Acad. Sci. USA 55, 134-141.
Rukayadi, Y., Shim, J.-S., and Hwang, J.-K. 2008. Screening of Thai medicinal plants for anticandidal activity. Mycoses 51, 308-312.
Sabir, M. and Bhide, N. 1971. Study of some pharmacologic actions of berberine. Ind. J. Phys. Pharm. 15, 111-132.
Talhouk, R.S., Karam, C., Fostok, S., El-Jouni, W., and Barbour, E.K. 2007. Anti-inflammatory bioactivities in plant extracts. J. Med. Food. 10, 1-10.
Thompson, D.S., Carlisle, P.L., and Kadosh, D. 2011. Coevolution of morphology and virulence in Candida species. Eukaryot. Cell 10, 1173-1182.
Wiemken, A., Schellenberg, M., and Urech, K. 1979. Vacuoles: The sole compartment of digestive enzymes in yeast (Saccharomyces cerevisiae)? Arch. Microbiol. 123, 23-25.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
출판사/학술단체 등이 한시적으로 특별한 프로모션 또는 일정기간 경과 후 접근을 허용하여, 출판사/학술단체 등의 사이트에서 이용 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.